Genomic Health Inc. (GHDX)

70.16
NASDAQ : Health Technology
Prev Close 70.59
Day Low/High 69.66 / 70.77
52 Wk Low/High 50.77 / 92.18
Avg Volume 640.90K
Exchange NASDAQ
Shares Outstanding 37.55M
Market Cap 2.65B
EPS 0.70
P/E Ratio 53.89
Div & Yield N.A. (N.A)

Latest News

New TAILORx Data, Published Today In JAMA Oncology, Add To Strong Evidence Base Reinforcing Unique Ability Of Oncotype DX Breast Recurrence Score® Test To Guide Chemotherapy Treatment

New TAILORx Data, Published Today In JAMA Oncology, Add To Strong Evidence Base Reinforcing Unique Ability Of Oncotype DX Breast Recurrence Score® Test To Guide Chemotherapy Treatment

Clinical Outcomes in Patients with High Recurrence Score® Results Presented Today in Oral Session at ESMO 2019 Congress

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test To Guide Chemotherapy For Node-negative And Node-positive Early-stage Breast Cancer

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test To Guide Chemotherapy For Node-negative And Node-positive Early-stage Breast Cancer

- Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy

URGENT: Monteverde & Associates PC Is Investigating The Following Transaction

URGENT: Monteverde & Associates PC Is Investigating The Following Transaction

NEW YORK, Aug. 9, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Genomic Health, Inc.

Exact Sciences Is Poised to Test New Highs on the Charts

Exact Sciences Is Poised to Test New Highs on the Charts

Here's how to trade the stock right now.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

NEW YORK, July 29, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc.

Shareholder Alert: Ademi & O'Reilly, LLP Investigates Whether Genomic Health, Inc. Has Obtained A Fair Price In Its Sale To Exact Sciences Corp.

Shareholder Alert: Ademi & O'Reilly, LLP Investigates Whether Genomic Health, Inc. Has Obtained A Fair Price In Its Sale To Exact Sciences Corp.

MILWAUKEE, July 29, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Genomic (Nasdaq: GHDX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Genomic to Exact Sciences.

Exact Sciences Reaches Deal to Acquire Genomic Health for $2.8 Billion

Exact Sciences Reaches Deal to Acquire Genomic Health for $2.8 Billion

Cancer diagnostics company Exact Sciences will acquire healthcare company Genomic Health for about $2.8 billion.

Genomic (GHDX) Alert: Johnson Fistel Investigates Proposed Sale Of Genomic Health, Inc.; Are Shareholders Getting A Fair Deal?

Genomic (GHDX) Alert: Johnson Fistel Investigates Proposed Sale Of Genomic Health, Inc.; Are Shareholders Getting A Fair Deal?

SAN DIEGO, July 29, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Genomic Health, Inc.

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.

Exact Sciences And Genomic Health To Combine, Creating Leading Global Cancer Diagnostics Company

Exact Sciences And Genomic Health To Combine, Creating Leading Global Cancer Diagnostics Company

Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth

Exact Sciences in Talks to Buy Genomic Health - Report

Exact Sciences in Talks to Buy Genomic Health - Report

Cancer diagnostics company Exact Sciences is in advanced talks to acquire Genomic Health for about $2.8 billion to strengthen its cancer-testing offerings, according to Bloomberg.

Genomic Health To Announce Second Quarter 2019 Financial Results And Host Conference Call On Thursday, August 1, 2019

Genomic Health To Announce Second Quarter 2019 Financial Results And Host Conference Call On Thursday, August 1, 2019

REDWOOD CITY, Calif., July 25, 2019 /PRNewswire/ -- Genomic Health, Inc.

Genomic Health Set To Join S&P SmallCap 600

Genomic Health Set To Join S&P SmallCap 600

NEW YORK, July 23, 2019 /PRNewswire/ -- Genomic Health Inc. (NASD: GHDX) will replace Electronics For Imaging Inc.

German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision For Oncotype DX Breast Recurrence Score® Test

German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision For Oncotype DX Breast Recurrence Score® Test

Reimbursement Decision Follows IQWiG's Recommendation Based on TAILORx Study Results

Secondary Analysis Of Landmark TAILORx Results, Published Today In The New England Journal Of Medicine, Affirms Unique Ability Of Oncotype DX Breast Recurrence Score® To Predict Chemotherapy Benefit, Guiding Adjuvant Therapy With Even Greater Precision

Secondary Analysis Of Landmark TAILORx Results, Published Today In The New England Journal Of Medicine, Affirms Unique Ability Of Oncotype DX Breast Recurrence Score® To Predict Chemotherapy Benefit, Guiding Adjuvant Therapy With Even Greater Precision

Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting TAILORx Continues to Elevate Oncotype DX ® to a New Global Standard with Increasing Utilization and...

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs For Determining Chemotherapy Benefit With The Oncotype DX Breast Recurrence Score® Test In Node-negative Breast Cancer

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs For Determining Chemotherapy Benefit With The Oncotype DX Breast Recurrence Score® Test In Node-negative Breast Cancer

New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial to be Presented at ASCO Annual Meeting Today REDWOOD...

Genomic Health To Present At The Jefferies 2019 Healthcare Conference

Genomic Health To Present At The Jefferies 2019 Healthcare Conference

REDWOOD CITY, Calif., May 29, 2019 /PRNewswire/ -- Genomic Health, Inc.

Genomic Health Reports First Quarter 2019 Financial Results And Recent Business Progress

Genomic Health Reports First Quarter 2019 Financial Results And Recent Business Progress

Delivered $108.8M in Revenue and Growth of 17.4 Percent

Genomic Health To Announce First Quarter 2019 Financial Results And Host Conference Call On Tuesday, May 7, 2019

Genomic Health To Announce First Quarter 2019 Financial Results And Host Conference Call On Tuesday, May 7, 2019

REDWOOD CITY, Calif., April 30, 2019 /PRNewswire/ -- Genomic Health, Inc.

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.

First Week Of January 2019 Options Trading For Genomic Health (GHDX)

First Week Of January 2019 Options Trading For Genomic Health (GHDX)

Investors in Genomic Health Inc saw new options become available this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GHDX options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:

First Week Of GHDX August 17th Options Trading

First Week Of GHDX August 17th Options Trading

Investors in Genomic Health Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GHDX options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $33.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Reaches Analyst Target Price

Genomic Health Reaches Analyst Target Price

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $32.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: B (Buy)